Physician

Lynn R Kong, MD

According to 2025 Medicare claims, Lynn Kong, MD (NPI: 1952356933) practices hematology/oncology in the Oxnard-Thousand Oaks-Ventura, CA market, with the plurality of this provider's patient population coming from Ventura, CA. This provider's primary affiliated billing organization is PMK MEDICAL GROUP, INC. (NPI: 1962405860; TIN: 770311552) and primary practice location at 93003-0712. Kong is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Kong's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 855 traditional Medicare patients, billed 9,558 HCPCS/CPT codes, and received $350,232 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,092 prescription claims across 195 beneficiaries totaling $3,620,333 in drug costs, led by Revlimid (Lenalidomide). DME data shows 13 claims. Open Payments data shows 165 records totaling $3,922. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing started with an early spike, then settled into a lower baseline, moving from $3,177,427 to $350,232. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,021,854 to $3,620,333. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $9,035 to $8,809.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	824	299,222	$3,177,427
2016	768	320,235	$2,986,543
2017	724	123,447	$1,621,797
2018	767	8,469	$412,670
2019	884	9,342	$464,647
2020	833	8,452	$449,907
2021	987	9,382	$516,589
2022	841	7,941	$379,699
2023	810	6,640	$264,401
2024	855	9,558	$350,232

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	145	820	$1,021,854
2016	164	928	$1,070,315
2017	172	1,005	$1,708,813
2018	172	1,051	$2,312,256
2019	175	1,144	$3,117,409
2020	201	1,238	$3,490,656
2021	200	1,074	$3,302,088
2022	201	1,291	$3,913,472
2023	194	1,098	$3,443,958
2024	195	1,092	$3,620,333

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	178	$56,803
2016	N/R	145	$39,095
2017	N/R	57	$14,986
2018	N/R	97	$13,552
2019	N/R	126	$11,909
2020	23	155	$11,600
2021	11	108	$7,347
2022	N/R	78	$2,311
2023	N/R	55	$1,907
2024	N/R	13	$245

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	592	1,433	$105
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	321	530	$69
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	788	2,129	$14
36415	Insertion of needle into vein for collection of blood sample	693	2,304	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	678	2,162	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	37	959	$580,518
Pomalyst	Pomalidomide	21	588	$478,392
Xtandi	Enzalutamide	33	990	$477,667
Jakafi	Ruxolitinib Phosphate	23	690	$376,305
Tagrisso	Osimertinib Mesylate	24	692	$365,462

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	165	$3,922	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lynn R. Kong, MD?

Tedicare shows public-source Medicare data for Lynn R. Kong, MD (NPI 1952356933), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lynn R. Kong, MD have ACO affiliation data?

Lynn R. Kong, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Lynn R. Kong, MD?

Lynn R. Kong, MD is linked to PMK MEDICAL GROUP, INC. (billing NPI 1962405860) in the available physician profile data.

Does Lynn R. Kong, MD have Open Payments data?

Lynn R. Kong, MD has 165 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.